Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vicals VaxfectinR Adjuvant – MarketWatch

The mouse-generated Pvs230 antibodies, incubated with P. vivax-infected human red blood cells and then fed to mosquitoes, statistically reduced the number of parasites and the infection rate in mosquitoes. A VaxfectinR-formulated malaria vaccine therefore has the potential to interfere with the transmission of P. vivax to humans through mosquitoes. This novel transmission-blocking approach may thereby protect the broader population from widespread malaria outbreaks. Further study of the vaccine candidate has been proposed by the authors.

via Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vicals VaxfectinR Adjuvant – MarketWatch.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s